ARYA Atherosclerosis (Feb 2022)

Troponin is a useful marker in clinical decision making in hospitalized patients with COVID-19 infections

  • Fahimeh Safarnezhad-Tameshkel,
  • Nima Motamed,
  • Mohammad Hadi Karbalaie-Niya,
  • Dhayaneethie Perumal,
  • Nader Rezaie,
  • Shirin Izadi,
  • Mitra Ranjbar,
  • Mahdi Yadollahzadeh,
  • Behnam Behdad,
  • Gholamreza Hemmasi,
  • Vahid Kaveh,
  • Ali Arash Anoushirvani,
  • Mojtaba Malek,
  • Behzad Farahani,
  • Ramin Eskandari,
  • Mahshid Panahi,
  • Mandana Rahimi,
  • Sepideh Emami,
  • Farhad Zamani,
  • Mohsen Farrokhpour

DOI
https://doi.org/10.22122/arya.v17i0.2191
Journal volume & issue
Vol. 17, no. 1

Abstract

Read online

BACKGROUND: COVID-19 was introduced by the World Health Organization (WHO) as a global pandemic. The spectrum of symptoms of the disease ranges from a mild cold to death. It has a higher mortality rate in people with a history of comorbidities, including cardiovascular disease (CVD) and can also contribute to cardiac injury. This study was conducted to evaluate the relationship between troponin levels as a cardiac marker and adverse outcomes in this disease.METHODS: The study sample included 438 patients hospitalized with COVID-19; however, the troponin data of 6 patients were not available. The need to be admitted to the intensive care unit (ICU), and death were considered the adverse outcome in patients with COVID-19. Troponin levels were checked in all patients on day 1 and day 3 of hospitalization. Multiple logistic regression analysis was performed to determine whether there was an independent association between the adverse outcomes and troponin enzyme in hospitalized patients with COVID-19.RESULTS: The mean age of patients was 61.29 ± 15.84 years. Among the 432 patients tested on day 1 of hospitalization, 24 patients (5.6%) tested positive (Troponin 1), and among the 303 patients tested on day 3, 13 patients (4.3%) tested positive (Troponin 2). Based on our results, Troponin 1 showed an independent association with both death (3.008 [95%CI = 1.091-8.290]; P = 0.033) and need for ICU admission (8.499 [95%CI = 3.316-21.788]; P < 0.001) in multiple logistic regression analysis. Moreover, the status of Troponin 2 had an independent significant association with both death (4.159 [95%CI = 1.156-14.961]; P = 0.029) and ICU admission (7.796 [95%CI = 1.954-31.097]; P = 0.004).CONCLUSION: Troponin showed a significant association with adverse outcomes in people who were hospitalized with COVID-19. The serial assessment of this enzyme from the time of hospitalization may improve the clinical decision making of clinicians.

Keywords